Evaluation of Disease Activity and Damage in Different Subtypes of Cutaneous Lupus Erythematosus Using the CLASI

September 2010 in “ Journal of the European Academy of Dermatology and Venereology ”

D Bein, Esther Kuehn, AM Meuth, Susanne Amler, Merle Haust, Fredrik Nyberg, Cristina Sauerland, Thomas A. Luger, Gisela Bonsmann, Annegret Kuhn

TLDR The CLASI is useful but needs revision to accurately assess all cutaneous lupus erythematosus subtypes.

The study evaluated the effectiveness of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in assessing disease activity and damage across different subtypes of cutaneous lupus erythematosus (CLE) in 50 patients (42 female, 8 male). Results indicated that the total CLASI activity and damage scores were significantly lower in patients with LE tumidus (LET) compared to those with acute CLE (ACLE), subacute CLE (SCLE), and chronic CLE (CCLE). Specific scores for erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis also varied significantly among the subtypes, with LET generally showing lower scores. The study concluded that while CLASI is a useful tool for analyzing CLE, it does not accurately assess all subtypes, suggesting a need for its revision.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus

27 citations , February 2009 in “Autoimmunity Reviews”

The European Society of Cutaneous Lupus Erythematosus created a questionnaire to standardize patient assessment and improve care for cutaneous lupus.

research Development of the CLASI as an Outcome Instrument for Cutaneous Lupus Erythematosus

52 citations , March 2007 in “Dermatologic Therapy”

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

research Dermatology Position Paper on the Revision of the 1982 ACR Criteria for Systemic Lupus Erythematosus

109 citations , November 2004 in “Lupus”

The paper concludes that the 1982 criteria for diagnosing systemic lupus erythematosus need updating to improve accuracy and involve dermatologists in the process.

Related Community Posts Join

6 / 14 results

community How do you use rosemary oil and peppermint oil?

in Question 6 upvotes 5 years ago

Rosemary oil and peppermint oil may promote hair growth and increase cutaneous blood flow, showing promise as treatments for androgenetic alopecia. Minoxidil 2% is also used for treating hair loss.

community Scientific evidence for Peppermint & Rosemary oils + My Experience

in Research/Science 114 upvotes 2 years ago

Natural treatments for hair loss, specifically peppermint oil and rosemary oil; how they can be used as a supplementary or alternative treatment to pharmaceuticals such as finasteride and minoxidil; and the personal experience of the user Divallo, who has seen an increase in density and thickness after using these oils for around 2.5 years. The post also touches on the potential antifungal properties of the oils and their effects on cutaneous blood flow.

community My experimental hair loss journey under medical supervision: finasteride/dutasteride, oral/topical minoxidil+tretinoin (3-month progress and hair transplant insights for those considering it)

in Treatment 42 upvotes 2 months ago

A 23-year-old discusses their hair loss treatment using finasteride, dutasteride, oral and topical minoxidil, and topical tretinoin under medical supervision. They stress stabilizing hair loss before a hair transplant and plan to continue the regimen for at least 18 months.

community high bloodpressure and crown thinning in early 20s

in Is this regrowth? 9 upvotes 1 year ago

A user with kidney disease and high blood pressure experienced hair thinning, especially around the vertex. They are currently using finasteride and oral minoxidil but are considering whether to resume blood pressure medication despite managing symptoms with diet and exercise.

community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

in Research/Science 110 upvotes 2 years ago

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

in Research/Science 63 upvotes 2 years ago

Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

Related Research

1 / 1 results

research Bullous Lesions in Patients with Cutaneous Lupus Erythematosus: A Clinicopathologic Study

1 citations , January 2021 in “Journal of the American Academy of Dermatology”

Careful histologic examination is crucial to differentiate types of bullous lesions in cutaneous lupus erythematosus.